HANSHOW/INTERGAMMA
15.5.2024 10:01:31 CEST | Business Wire | Press release
Hanshow, a global leader in digital retail solutions, has announced its exclusive partnership with Intergamma, the market leader in the Benelux DIY sector, initiating the official installation of Hanshow's Electronic Shelf Labels (ESLs) in November 2023. This collaboration aims to deliver a unique and seamless shopping experience for customers across all channels. This collaboration signals an exciting development in the retail industry as it expands Hanshow's presence in the non-food retail sector with Intergamma operating under the prominent Gamma and Karwei brands, with nearly 400 stores in the Netherlands and Belgium. As of February 2024, installation progress includes the successful completion of ESL deployments in all 128 Karwei stores, with installations for Gamma outlets actively ongoing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240504881462/en/
Hanshow ESLs at Intergamma. (Photo: Business Wire)
Joining forces with Hanshow and utilizing the cutting-edge electronic shelf label (ESL) solution, Intergamma will further streamline in-store operations and enhance the customer journey in its stores for certain categories. As the largest DIY online platform in the Benelux region, Intergamma is committed to breaking boundaries and offering seamless shopping from online search to in-store purchases. Hanshow's ESL solution provides real-time synchronization of product information and pricing across all channels, reducing pricing discrepancies and improving the overall in-store experience.
This partnership marks a significant milestone for both companies. Through this alliance, Intergamma will leverage Hanshow's ESL technology to provide customers with an enhanced smart shopping experience for selected categories.
The key advantages of Hanshow's ESL solutions include:
- Innovation in ESL: Hanshow is at the forefront of ESL technology, offering holistic ESL solutions specifically for the DIY industry.
- Technology Leadership: Hanshow's new generation HiLPC protocol offers retailers top-tier ESL management, rapid response times, reliable service, and precise cross-channel pricing to enhance O2O capabilities.
- Industry Expertise: Leveraging extensive experience in the DIY sector, Hanshow aids Intergamma in advancing its digital transformation efforts.
Intergamma's values of fostering a sustainable future is also aligned with the introduction of Hanshow's eco-friendly operational model.
Jurre Mulder, Chief Digital & Technology Officer at Intergamma said, “We are happy to announce our partnership with renowned supplier digital store solutions Hanshow. Through this collaboration, Intergamma demonstrates its dedication to incorporating cutting-edge technology and improving the shopping experience for its devoted customers. In the next 9 months we will roll out ESL in our stores for the paint and electrical tools departments. We're excited to raise the bar for retail innovation together.”
“This collaboration with Intergamma is an important milestone in our journey to expand into the DIY retail field,” said Liangyan Li, SVP, Head of Global Sales, Hanshow. “This partnership is a great starting point, and in the future, Intergamma and Hanshow will continue to collaborate deeply, accelerating innovation and integration, and jointly promoting the digitization and sustainable development of the DIY retail industry.”
About Intergamma
Intergamma B.V. is the market leader in the do-it-yourself market in the Benelux with its retail formulas GAMMA Netherlands, GAMMA Belgium and KARWEI. With a strong store network and cross-channel strategy, Intergamma inspires and helps its customers to turn their house and garden into a comfortable and sustainable home. Learn more: www.intergamma.nl
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240504881462/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom